FAG
BDTX icon

Fortitude Advisory Group’s Black Diamond Therapeutics BDTX Stock Holding History

Fortitude Advisory Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-160
Closed – – 313
2022
Q1 		$0 Hold
160
– – ﹤0.01% 1517
2021
Q4 		$1K Buy
+160
New +$1.12K ﹤0.01% 1460

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Fortitude Advisory Group's BDTX Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Black Diamond Therapeutics (BDTX) in Q2 2022, closing a stake of 160 shares.

Fortitude Advisory Group first reported a position in BDTX in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 74 funds tracked by Wall St. Rank hold BDTX as of Q2 2022.

  • Fortitude Advisory Group reported no remaining Black Diamond Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 160 Black Diamond Therapeutics shares in Q2 2022.
  • Fortitude Advisory Group first reported a position in Black Diamond Therapeutics in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's Black Diamond Therapeutics position peaked at $1K in Q4 2021.
  • 74 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.